 |
Kevin KANG Boehringer Ingelheim China & HK Vice President, Human Resources
Kevin Kang serves as Vice President, Human Resources, for Boehringer Ingelheim China and Hong Kong since Oct. 2010. Prior to Boehringer Ingelheim, Kevin was HR Vice President at Tyco Electronics as Business Partner for its largest buisness unit of Communications & Industrial Solutions (CIS) in Asia Pacific. Kevin started with Tyco Electronics in 2004 and had been in roles of HR Shared Services Director, HR VP for China and Greater China respectively.
Prior to joining Tyco Electronics, Kevin began his HR career in early 90’s in Toronto, Canada, and has been working in various HR positions in Toronto, Hong Kong and Taiwan before he returned back to Shanghai in 2004, and early in his career, he also worked in academia in Beijing China and a marketing position in New Jersey USA.
Mr. Kang received a bachelor’s degree in Economics from the University of International Business and Economics in Beijing in 1982, a master’s degree in International Management from the American Graduate School of International Management (now as “Thunderbird School of Global Management”), Arizona, U.S. in 1984, and a Master of Science in Human Resources Management from the University of British Columbia, Canada, in 1994. |
 |
The Boehringer Ingelheim group is one of the world's 20 leading harmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.
Boehringer Ingelheim's business in China is focusing on prescription medicines, consumer healthcare , animal health and international procurement, covering major markets in the country. The company spares no effort in bringing innovative pharmaceutical products to China market, and as a result, Boehringer Ingelheim has obtained a strong recognition for the excellence of its product pipeline covering therapeutic areas ranging from respiratory, cardiovascular to central nerve system medicines. |
|
|
|
SPEAKERS